New application of inhibitor in promotion of colorectal cancer immunotherapy

By combining IGF1R inhibitor I-OMe-Tyrphostin AG 538 and immune checkpoint inhibitor, the problem of low response rate for colorectal cancer immunotherapy is solved, significantly improving the sensitivity and efficacy of cancer cells to immunotherapy, and activate anti-tumor immunity , effectively inhibits the growth of cancer cells.

CN118948827APending Publication Date: 2024-11-15THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411278909.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-12
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The response rate of immunotherapy in colorectal cancer is not high, especially patients with stable microsatellites or normal mismatch repair function, which responds poorly to existing immunotherapy drugs.

Method used

Using IGF1R inhibitor I-OMe-Tyrphostin AG 538 or its related derivatives in combination with immune checkpoint inhibitors, such as PD-1 monoclonal antibody or CTLA-4 monoclonal antibody, promotes colorectal cancer immune cell infiltration and improves the sensitivity of immunotherapy .

Benefits of technology

Significantly improve the sensitivity of colorectal cancer to immunotherapy, promote lymphotoxic T cell infiltration, activate innate immune pathways, overcome immune therapy resistance, effectively inhibit cancer cell growth, and improve patient efficacy and prognosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948827A_ABST
    Figure CN118948827A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicine health, and provides a new application of an inhibitor in promoting colorectal cancer immunotherapy, including a pharmaceutical composition for promoting colorectal cancer immune cell infiltration of mammals or human beings and improving the sensitivity of colorectal cancer immunotherapy of mammals or human beings. The pharmaceutical composition comprises an effective amount of an IGF1R inhibitor I-OMe-Tyrphostin AG 538 (AG-538) or a related derivative of the IGF1R inhibitor I-OMe-Tyrphostin AG 538 (AG-538) as an active ingredient, when the immune checkpoint inhibitor and AG-538 are used at the same time, the sensitivity of colorectal cancer to immunotherapy can be remarkably improved, infiltration of lymphotoxic T cells is promoted, an innate immune pathway is activated, anti-tumor immunity is promoted, immunotherapy resistance is overcome, development of a novel immune combined therapy strategy is facilitated, growth of colorectal cancer is effectively inhibited, and the immune checkpoint inhibitor has a good application prospect. The curative effect and prognosis of colorectal cancer patients are improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical health technology, and specifically, is a use of an IGF1R inhibitor I-OMe-Tyrphostin AG 538 (hereinafter referred to as AG-538) or its related derivatives in the preparation of drugs for promoting the infiltration of immune cells of colorectal cancer in mammals or humans and improving the sensitivity of immunotherapy of colorectal cancer in mammals or humans. Background Art

[0002] Colorectal cancer (CRC) is one of the malignant tumors with high morbidity and mortality worldwide. In my country, colorectal cancer has become the second most common malignant tumor after lung cancer, causing a heavy disease burden on society and families. Tumor immunotherapy is a treatment method that uses the body's own immune system to identify and attack tumor cells. In recent years, tumor immunotherapy has made significant progress and has become an important part of many cancer treatments. Common tumor immunotherapy strategies include immune checkpoint inhibitors (ICIs), cytotoxic T-cell therapies, and cancer vaccines.

[0003] In the immunotherapy of colorectal cancer, the application of ICIs is relatively common and has brought new hope to some patients; however, the response rate of immunotherapy in colorectal cancer is not high, especially for patients with microsatellite stable (MSS) or normal mismatch repair function (pMMR), who respond poorly to existing immunotherapy drugs; therefore, it is of great clinical significance to study new treatment strategies and drugs to improve the treatment effect of colorectal cancer and the quality of life of patients.

[0004] To this end, those skilled in the art have proposed a new use of an inhibitor in promoting immunotherapy of colorectal cancer to solve the problems raised by the background art. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides a new use of an inhibitor in promoting immunotherapy for colorectal cancer, so as to solve the problem that the response rate of immunotherapy in colorectal cancer in the prior art is not high, especially patients with microsatellite stability (MSS) or normal mismatch repair function (pMMR), have a poor response to existing immunotherapy drugs.

[0006] An object of the present invention is to provide a pharmaceutical composition for promoting the infiltration of immune cells in colorectal cancer of mammals or humans and improving the sensitivity of immunotherapy of colorectal cancer of mammals or humans, wherein the pharmaceutical composition comprises an effective amount of IGF1R inhibitor I-OMe-Tyrphostin AG 538 (AG-538) or its related derivatives as an active ingredient.

[0007] Preferably, the pharmaceutical composition further comprises one or more immune checkpoint inhibitors.

[0008] Preferably, the immune checkpoint inhibitor includes PD-1 monoclonal antibody, CTLA-4 monoclonal antibody or a combination thereof.

[0009] Another object of the present invention is to provide a pharmaceutical composition that promotes immune cell infiltration in colorectal cancer of mammals or humans and improves the sensitivity of colorectal cancer immunotherapy in mammals or humans. The pharmaceutical composition is used in the treatment of colorectal cancer in mammals or humans to enhance immune cell infiltration and improve the sensitivity of immunotherapy.

[0010] Preferably, it comprises administering an effective amount of AG-538 or its related derivatives to a mammal or a human in need thereof.

[0011] Preferably, the administration method includes but is not limited to oral administration, injection or local administration.

[0012] Compared with the prior art, the present invention has the following beneficial effects:

[0013] The immune checkpoint inhibitor of the present invention, when used simultaneously with AG-538, can significantly enhance the sensitivity of colorectal cancer to immunotherapy, promote the infiltration of lymphotoxic T cells, activate innate immune pathways, promote anti-tumor immunity, overcome resistance to immunotherapy, and contribute to the development of new immunotherapy combination strategies, effectively inhibit the growth of colorectal cancer, and improve the efficacy and prognosis of colorectal cancer patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1The figure is a result diagram showing that AG-538 of the present invention can activate anti-tumor immunity under in vitro culture conditions, wherein A is the mRNA expression level of multiple chemokines under the action of AG-538; B is the effect of AG-538 on the viability of colon cancer cells at different action concentrations; C is the effect of AG-538 on the viability of colon cancer cells at different action times; D is a cell density diagram and a statistical diagram after co-culture of HT29 cells and PBMC cells; E is a statistical diagram of the content of IFN-γ / TNF-α / granzyme B in the supernatant of co-culture of HT29 cells and PBMC cells; F is a cell density diagram and a statistical diagram after co-culture of HCT116 cells and PBMC cells; G is a statistical diagram of the content of IFN-γ / TNF-α / granzyme B in the supernatant of co-culture of HCT116 cells and PBMC cells;

[0015] Figure 2 The figure is a comparative diagram of the anti-tumor effect of AG-538 of the present invention in the immunodeficient and immune normal mouse models; wherein A is a schematic diagram of the constructed immunodeficient nude mouse subcutaneous tumor model; B is a tumor growth curve of the control group and the AG-538 treatment group in the nude mouse subcutaneous tumor experiment; C is a tumor photo and weight statistical chart of the tumor experiment of the control group and the AG-538 treatment group in the nude mouse subcutaneous tumor experiment; D is a schematic diagram of the constructed immune normal C57BL / 6J mouse subcutaneous tumor model; E is a tumor growth curve of the control group and the AG-538 treatment group in the C57BL / 6J mouse subcutaneous tumor experiment; F is a tumor photo and weight statistical chart of the control group and the AG-538 treatment group in the C57BL / 6J mouse subcutaneous tumor experiment;

[0016] Figure 3 The results of the present invention that AG-538 can effectively inhibit tumor growth and promote immunotherapy in a normal immune mouse model; A is a schematic diagram of the constructed normal immune C57BL / 6J mouse subcutaneous tumor model and PD-1 monoclonal antibody treatment; B is a tumor growth curve of the control group, AG-538 monotherapy group, PD-1 monoclonal antibody treatment group and AG-538 combined with PD-1 monoclonal antibody group in the C57BL / 6J mouse subcutaneous tumor experiment; C is a photo of four groups of tumors in the C57BL / 6J mouse subcutaneous tumor experiment; D is a statistical graph of the weight of four groups of tumors in the C57BL / 6J mouse subcutaneous tumor experiment;

[0017] Figure 4The results of the C57BL / 6J mouse subcutaneous tumor formation experiment of the present invention, in which AG-538 treatment can significantly increase the degree of immune cell infiltration in the tumor; wherein A is a CD3-positive immunohistochemistry and density statistical analysis diagram in the control group, the AG-538 monotherapy group, the PD-1 monoclonal antibody treatment group, and the AG-538 combined with the PD-1 monoclonal antibody group; B is a CD4-positive immunohistochemistry and density statistical analysis diagram in the four groups of tumors; C is a CD8-positive immunohistochemistry and density statistical analysis diagram in the four groups of tumors; D is a granzyme B-positive immunohistochemistry and density statistical analysis diagram in the four groups of tumors;

[0018] Figure 5 The results of the present invention show that AG538 can cause DNA damage and increase the free DNA content in the cytoplasm, wherein A is a statistical diagram of evaluating the degree of DNA damage of AG-538 at different action times by immunofluorescence; B is a statistical diagram of evaluating the degree of DNA damage of AG-538 at different action concentrations by immunofluorescence; C is a statistical diagram of evaluating the cytoplasmic DNA content of AG-538 at different action times by quantitative PCR; D is a statistical diagram of evaluating the cytoplasmic DNA content of AG-538 at different action concentrations by quantitative PCR;

[0019] Figure 6 The results of AG-538 of the present invention activating the STING innate immune pathway are shown in Figure 1, wherein A is an immunoblotting method for detecting the activation of the intracellular STING pathway at different concentrations of AG-538; B is an immunoblotting method for detecting the activation of the intracellular STING pathway at different action times of AG-538; C is a quantitative PCR method for detecting the mRNA levels of various STING pathway-related cytokines in cells after AG-538 treatment; D is an enzyme-linked immunosorbent assay (ELISA) for detecting the secretion of various STING pathway-related cytokines into the cell supernatant after AG-538 treatment;

[0020] Figure 7 Schematic diagram of the invention showing that the interference with the STING pathway can block the promoting effect of AG-538 on various cytokines; wherein A is a quantitative PCR method for detecting the content and statistical analysis of the mRNA levels of various STING pathway-related cytokines after STING knockout cells are treated with AG-538 or cells are treated with AG-538 and the STING inhibitor H-151 at the same time; D is an enzyme-linked immunosorbent assay (ELISA) method for detecting the content and statistical analysis of various STING pathway-related cytokines secreted into the cell supernatant after STING knockout cells are treated with AG-538 or cells are treated with AG-538 and the STING inhibitor H-151 at the same time;

[0021] Figure 8The figures are effect diagrams of interfering with the STING pathway under in vitro conditions of the present invention on the activation of anti-tumor immunity by AG-538; wherein A is a cell density diagram and a statistical diagram after AG-538 and the STING pathway inhibitor H-151 are added to the co-cultured colorectal cancer cells and PBMC cells; B is a statistical diagram of the IFN-γ / TNF-α / granzyme B content in the supernatant after AG-538 and the STING pathway inhibitor H-151 are added to the co-cultured colorectal cancer cells and PBMC cells; C is a cell density diagram and a statistical diagram of wild-type or STING knockout colorectal cancer cells co-cultured with PBMC and treated with AG-538; D is a statistical diagram of the IFN-γ / TNF-α / granzyme B content in the supernatant of cells co-cultured with PBMC and treated with AG-538 after wild-type or STING knockout colorectal cancer cells are co-cultured with PBMC;

[0022] Fig. 9 The figures show that interfering with the STING pathway in the subcutaneous tumor model of immune normal mice can affect the effect of AG-538 in activating anti-tumor immunity and promoting immunotherapy; A is the tumor growth curve and statistical graph of the tumor group and the corresponding control group injected with AG-538, PD-1 monoclonal antibody and STING pathway inhibitor H-151 simultaneously in the subcutaneous tumor model of immune normal mice; B is the statistical analysis graph of the tumor weight in the above-mentioned groups; C is the tumor growth curve and statistical graph of each group after subcutaneous inoculation of STING wild-type and knockout colorectal cancer cells in immune normal mice, respectively, and then treated with AG-538 and PD-1 monoclonal antibody; D is the statistical analysis graph of the tumor weight in the above-mentioned groups. DETAILED DESCRIPTION

[0023] The following embodiments of the present invention are described in further detail in conjunction with the accompanying drawings and examples. The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention.

[0024] The present invention provides use of an IGF1R inhibitor I-OMe-Tyrphostin AG 538 (hereinafter referred to as AG-538) or its related derivatives in the preparation of a drug for promoting the infiltration of immune cells of colorectal cancer in mammals or humans and improving the sensitivity of immunotherapy of colorectal cancer in mammals or humans; and also provides a pharmaceutical composition for promoting the infiltration of immune cells of colorectal cancer in mammals or humans and improving the sensitivity of immunotherapy of colorectal cancer in mammals or humans.

[0025] like Figures 1 to 9 As shown:

[0026] Example 1: Evaluation of the effect of AG-538 on immune cell tumor killing and immunotherapy in vitro

[0027] Fresh peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors using Ficol-Paque Plus reagent (Solaibao, China); 48-well plates were pre-coated with CD3 antibody (5 μg / mL, Biolegend, USA) for 4 h, and then 1×10 5 PBMC cells were added and activated with 100 IU / mL IL-2 (Novoprotein, China); colorectal cancer cells were then co-cultured with PBMCs in a 1:5 ratio in a 48-well plate, and each experimental setting was repeated three times; PD-1 monoclonal antibody Pembrolizumab (100 μg / mL) or AG-538 (1 μM) was added to the culture system; after 2 days of co-culture, PBMCs were removed and the remaining tumor cells were stained with crystal violet; then the relative staining intensity was analyzed using ImageJ software; the results showed that AG-538 could enhance the killing effect of PBMC on colorectal cancer cells, and the combined use could further increase the efficacy of PD-1 monoclonal antibody, such as Figure 1 shown.

[0028] Example 2: Evaluation of the anti-tumor effect of AG-538 in immunodeficient and immune-competent mouse models under in vivo conditions

[0029] Male BALB / c nude mice or C57BL / 6J mice were used to construct subcutaneous tumor models. Each mouse was injected subcutaneously with 1×10 6 MC38 mouse intestinal cancer cells were injected; 7 days after injection, the mice were randomly divided into a control group and an AG-538 treatment group, and the tumor size was measured every 2 to 3 days and calculated according to the formula 0.5×length×width 2 Calculate tumor volume; when the tumor volume exceeds 2000mm 3 The mice were euthanized when the tumor volume was 1.34 μg / mL. The results showed that in the nude mouse experiment, there was no significant difference in the tumor growth volume between the control group and the AG-538-treated group. However, in the immune-normal C57BL / 6J mouse model, AG-538 treatment could significantly inhibit tumor growth. Figure 2 shown.

[0030] Example 3: Anti-tumor effect of intraperitoneal injection of AG-538 combined with PD-1 monoclonal antibody

[0031] Male C57BL / 6J mice were used to construct a subcutaneous tumor xenograft model. Each mouse was injected subcutaneously with 1×10 6MC38 cells; 7 days after injection, the mice were randomly divided into a control group, an AG-538 monotherapy group, a PD-1 monoclonal antibody treatment group, and an AG-538 combined with PD-1 monoclonal antibody treatment group, wherein anti-mouse PD-1 antibody (Selleck, A2122) and IgG isotype control (Selleck, A2123) were administered by intraperitoneal injection at a dose of 200 μg on the 7th, 9th, and 11th days after injection, and AG-538 (MedChemExpress, HY-135680) was administered by intraperitoneal injection at a dose of 100 μg and 200 μg per mouse in 200 μL of 10% Tween-80 in PBS; the tumor volume was measured every 2 to 3 days after one week of inoculation, and the tumor volume was calculated according to the formula 0.5×length×width 2 Calculate tumor volume; when the tumor volume exceeds 2000mm 3 The mice were euthanized when AG-538 was used alone. The results showed that AG-538 not only inhibited tumor growth when used alone, but also enhanced the sensitivity of tumors to PD-1 monoclonal antibodies, further improving the efficacy of immunotherapy. Figure 3 shown.

[0032] Example 4: Immunohistochemical staining to detect the level of immune cell infiltration in tumors after AG-538 treatment

[0033] Tumor specimens from the control group, AG-538 monotherapy group, PD-1 monoclonal antibody treatment group, and AG-538 combined with PD-1 monoclonal antibody treatment group were collected and fixed overnight with 10% formaldehyde buffer, then embedded in paraffin, and cut into 4-μm-thick sections; then, the sections were deparaffinized twice with xylene and rehydrated in gradient concentrations of ethanol; antigen retrieval was performed in EDTA antigen retrieval solution; then 3% hydrogen peroxide was used and blocked with serum-free protein blocking agent (DAKO); primary antibodies were incubated at appropriate dilutions (CD3, 1:100; CD8, 1:200; CD4, 1:100; Granzyme B, 1:100) at 37°C for 50 minutes, followed by incubation with secondary antibodies at room temperature for 30 minutes, and then the sections were stained with DAB (3,3'-diaminobenzidine); after staining, the sections were scanned with a digital slide scanner and the immunohistochemical positive density values ​​were analyzed and compared using imageJ software; the results showed that the AG-538 treatment group could increase the level of immune cell infiltration in the tumor, especially CD8+ lymphocytes, and the activated lymphocytes represented by granzyme B positive also increased significantly, such as Figure 4 shown.

[0034] Example 5: Immunofluorescence observation of DNA damage in AG-538 cells

[0035] Colorectal cancer cells were treated with AG-538 for different durations or concentrations, then fixed with 4% paraformaldehyde for 30 minutes and washed twice with PBS; subsequently, the samples were incubated with Triton-X 100 at room temperature for 30 minutes, washed twice with PBS, and then incubated in 3% bovine serum albumin (BSA) for 60 minutes; thereafter, the samples were incubated with the primary antibody for the DNA damage marker γH2AX at 4°C overnight; the secondary antibody was added and incubated for 1 hour at room temperature in the dark; finally, images were captured using a Nikon fluorescence microscope; the results showed that with the increase in the concentration or duration of AG-538, the degree of DNA damage in colorectal cancer cells gradually increased, such as Figure 5 Middle A and Figure 5 As shown in B.

[0036] Example 6: Quantitative PCR detection of intracellular free DNA content

[0037] Colorectal cancer cells treated with AG-538 for different time periods or concentrations were collected, resuspended in PBS after centrifugation, and centrifuged again. The supernatant was discarded and cytoplasmic extraction reagent was added, followed by centrifugation to remove nuclei and intact cells. The supernatant was transferred and centrifuged at high speed to obtain cytoplasmic DNA. POLG in genomic DNA was then detected and quantified by quantitative PCR, with the upstream primer GCTGCACGAGCAAATCTTCG and the downstream primer GTCCAGGTTGTCCCCGTAGA. The results showed that with the increase in the action time and concentration of AG-538, the content of cytoplasmic free DNA increased significantly, such as Figure 5 Middle C and Figure 5 As shown in D.

[0038] Example 7: Western blot detection of the activation state of the STING pathway in cells

[0039] Colorectal cancer cells treated with AG-538 for different time periods or concentrations were collected, washed once with PBS after centrifugation, and then directly lysed in ice-cold RIPA lysis buffer containing the following substances: 150mM NaCl, 5mM EDTA, 50mM TrispH 8.0, 1% NP-40, 0.5% SDS and 0.1% SDS, supplemented with 1mM DTT, EDTA-free protease inhibitor (Sigma), incubated on ice for 15 minutes with occasional shaking, and then centrifuged at 16,000g for 10 minutes at 4°C to clarify the lysate; protein concentration was determined by BCA kit (ThermoFisher Scientific); equal amounts of protein were diluted into 1X SDS-PAGE addition buffer, boiled at 95°C for 10 minutes, and then loaded into Criterion TGX The proteins were then transferred to a nitrocellulose membrane (BioRad); the membrane was blocked with 5% skim milk powder for 1 hour at room temperature, and then incubated with primary antibodies overnight at 4°C, using antibodies diluted in 3% bovine serum albumin; the primary antibodies used included anti-human / mouse cGAS (Cat. No. 29958-1-AP, Proteintech), anti-human / mouse STING (Cat. No. 19851-1-AP, Proteintech), anti-human p-STING (Ser366) (No. 19781, CST), anti-human / mouse TBK1 (Cat. No. 28397-1-AP, Proteintech), anti-human / mouse p-TBK1 (Ser172 )(No. 5483, CST), anti-human / mouse IRF3 (Cat. No. 66670-1-Ig, Proteintech), anti-human / mouse p-IRF3 (Ser396) (Cat. No. 29528-1-AP, Proteintech) and anti-human / mouse GAPDH (Cat. No. 60004-1-Ig, Proteintech); the membrane was then washed three times in TBST for 5 minutes each time, and then incubated with the corresponding secondary antibody HRP conjugate diluted in 5% skim milk powder at room temperature for 1 hour; the membrane was washed three times in TBST and then developed with ECL solution; the results showed that with the increase of AG-538 action time and concentration, the STING pathway in colorectal cancer cells was significantly activated, such as Figure 6 Middle A and Figure 6 As shown in B.

[0040] Example 8: Quantitative PCR detection of chemokine expression levels

[0041] The cells of the control group and AG-538-treated group were collected and washed with PBS, RNA was extracted from them using TRIzol reagent, and cDNA was synthesized using ReverTra Ace qPCR RT Master Mix (TOYOBO). Quantitative real-time PCR was performed using SYBR Green Realtime PCR Master Mix (TOYOBO) on Roche Lightcycler480, and 2 -ΔΔCT The calculation method was used for analysis; GAPDH was used as the reference gene for standardization; the primer sequences of each gene are as follows:

[0042] Genes Forward(5'-3') Reverse(5'-3') CCL2 CAGCCAGATGCAATCAATGCC TGGAATCCTGAACCCACTTCT CCL3 AGTTCTCTGCATCACTTGCTG CGGCTTCGCTTGGTTAGGAA CCL4 CTGTGCTGATCCCAGTGAATC TCAGTTCAGTTCCAGGTCATACA CCL5 CCAGCAGTCGTCTTTGTCAC CTCTGGGTTGGCACACACTT CXCL9 CCAGTAGTGAGAAAGGGTCGC AGGGCTTGGGGCAAATTGTT CXCL10 GTGGCATTCAAGGAGTACCTC TGATGGCCTTCGATTCTGGATT ISG15 CGCAGATCACCCAGAAGATCG TTCGTCGCATTTGTCCACCA IFNB1 ATGACCAACAAGTGTCTCCTCC GGAATCCAAGCAAGTTGTAGCTC IRF9 GCCCTACAAGGTGTATCAGTTG TGCTGTCGCTTTGATGGTACT IFIT1 AGAAGCAGGCAATCACAGAAAA CTGAAACCGACCATAGTGGAAAT GAPDH GACTCATGACCACAGTCCATGC AGAGGCAGGGATGATGTTCTG

[0043] The results showed that AG-538 could significantly promote the expression of multiple chemokines and STING-related cytokines, such as Figure 1 Middle A and Figure 6 As shown in C.

[0044] Example 9: ELISA detection of the content of T cell activation-related factors and chemokines in the culture supernatant

[0045] The PBMC tumor cell co-culture supernatant of the control, PD-1 monoclonal antibody, AG-538 and combination drug groups was collected and diluted with PBS at a ratio of 1:5. 100 μL was added to each well of the 96-well plate and incubated for 1 hour. After washing three times, 50 μL was added AG-538 was added with detection antibodies for IFN-γ (Biolegend, Catalog No. 430107), TNF-α (Biolegend, Catalog No. 430207) and granzyme B (Biolegend, Catalog No. 439207) and incubated at room temperature for 1 hour; then washed three times again, followed by adding 100 μL of avidin horseradish peroxidase (HRP) and incubating for 30 minutes; after another three washes, 100 μL of tetramethylbenzidine (TMB) substrate solution was added and incubated at room temperature for 15 minutes; finally, 100 μL of stop solution was added, and the absorbance of the plate was read at a wavelength of 450 nm using a Bio-Rad plate reader; the results showed that AG-538 significantly promoted T cell activation and the secretion of cytotoxic factors IFN-γ, TNF-α and granzyme B, such as Figure 1 Middle E and Figure 1 As shown in G;

[0046] In addition, the culture supernatants of colorectal cancer cells in the control group and the AG-538-treated group were collected and diluted at a ratio of 1:5 before analysis. 100 μL of each well was added to a 96-well plate and incubated for 1 hour. After washing three times, 50 μL of IFN-β (Biolegend, Catalog No. 449507), CXCL10 (Biolegend, Catalog No. 439907), and CCL5 (Biolegend, Catalog No. 440807) detection antibodies were added and incubated at room temperature for 1 hour. Then, the plates were washed again. Three times, followed by the addition of 100 μL of avidin horseradish peroxidase (HRP) and incubation for 30 minutes; after another three washes, 100 μL of tetramethylbenzidine (TMB) substrate solution was added and incubated at room temperature for 15 minutes; finally, 100 μL of stop solution was added and the absorbance of the plate was read at a wavelength of 450 nm using a Bio-Rad plate reader; the results showed that after AG-538 treatment, the secretion of IFN-β, CXCL10, and CCL5 in colorectal cancer cells was significantly increased, as shown in Figure 2. Figure 6 As shown in D.

[0047] Example 10: Evaluation of the effect of AG-538 on immune cell tumor killing and immunotherapy after STING pathway intervention in vitro

[0048] Fresh peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors using Ficol-Paque Plus reagent (Solaibao, China); 48-well plates were pre-coated with CD3 antibody (5 μg / mL, Biolegend, USA) for 4 h, and then 1×10 5 PBMC cells were added with 100 IU / mL IL-2 (Novoprotein, China) for activation; wild-type colorectal cancer cells or STING knockout colorectal cancer cells were then co-cultured with PBMCs at a ratio of 1:5 in 48-well plates, and each experimental setting was repeated three times; H-151 (1 μM) or combined with AG-538 (1 μM) was added to the culture system; after 2 days of co-culture, PBMCs were removed and the remaining tumor cells were stained with crystal violet; then the relative staining intensity was analyzed using ImageJ software; the results showed that after the STING pathway was inhibited, the effect of AG-538 on promoting PBMC to kill tumor cells was also blocked, such as Figure 8 As shown; this indicates that the effect of AG-538 in activating anti-tumor immunity is dependent on the STING pathway.

[0049] Example 11: Evaluation of the anti-tumor effect of intraperitoneal injection of AG-538 combined with PD-1 monoclonal antibody after the tumor STING pathway was interfered

[0050] Male C57BL / 6J mice were used to establish a subcutaneous tumor transplantation model. Each mouse was injected subcutaneously with 1×10 6 One week after injection, the wild-type tumor mice were randomly divided into control group, AG-538 treatment group, AG-538 combined with PD-1 monoclonal antibody group, H-151 group, H-151 and AG-538 treatment group, and H-151 and AG-538 combined with PD-1 monoclonal antibody group.

[0051] The STING knockout tumor mice were divided into a control group, an AG-538 treatment group, and an AG-538 combined with PD-1 monoclonal antibody group. The tumor size was measured every 2 to 3 days and the formula was 0.5 × length × width. 2 Calculate tumor volume; when the tumor volume exceeds 2000mm 3 The mice were euthanized at 7, 9, and 11 days after injection. Anti-mouse PD-1 antibody (Selleck, A2122) and IgG isotype control (Selleck, A2123) were administered by intraperitoneal injection at a dose of 200 μg on days 7, 9, and 11 after injection. AG-538 (MedChemExpress, HY-135680) and STING inhibitor H-151 (MedChemExpress, HY-112693) were administered by intraperitoneal injection at a dose of 100 μg and 200 μg, respectively, in 200 μL of 10% Tween-80 in PBS. The results showed that in the tumor-bearing mouse model, after the tumor STING pathway was inhibited and interfered, the anti-tumor effect of AG-538 was significantly weakened, and it was also unable to further enhance the sensitivity of immunotherapy, such as Fig. 9 shown.

[0052] In summary:

[0053] 1. AG-538 can activate anti-tumor immunity and inhibit the progression of colorectal cancer. When colorectal cancer cells were co-cultured with PBMC, the addition of AG-538 significantly enhanced the activity of PBMC in killing tumor cells and promoted the activation of T cells to release killer particles such as granzymes, tumor necrosis factor and interferon. In in vivo experiments, the anti-tumor effect of AG-538 depends on a sound immune system. Therefore, in mice with normal immune function, AG-538 can significantly inhibit the growth of colorectal cancer, increase the infiltration level of immune cells in tumors, and improve the efficacy of PD-1 monoclonal antibodies.

[0054] 2. AG-538 can promote the anti-tumor immunity and immunotherapy of colorectal cancer by activating the STING innate immune pathway. First, we used Western blot detection to see that the key molecules of the STING pathway were activated after AG-538 treated colorectal cancer cells, and quantitative PCR and ELISA detection found that the expression and secretion of cytokines related to this pathway increased. By constructing a mouse transplant tumor model, we found that when the STING pathway was interfered with by pharmacological or genetic means, the effect of AG-538 on enhancing anti-tumor immunity would be blocked.

[0055] The embodiments of the present invention are provided for the purpose of illustration and description. Although the embodiments of the present invention have been shown and described above, it can be understood that the above embodiments are exemplary and cannot be understood as limitations of the present invention. Ordinary technicians in this field can change, modify, replace and modify the above embodiments within the scope of the present invention.

Claims

1. A pharmaceutical composition for promoting the infiltration of immune cells in mammalian or human colorectal cancer and improving the sensitivity of immunotherapy for mammalian or human colorectal cancer, It is characterized in that The pharmaceutical composition comprises an effective amount of IGF1 R inhibitor I-OMe-Tyrphostin AG 538 or its related derivatives as an active ingredient.

2. The pharmaceutical composition according to claim 1, It is characterized in that The pharmaceutical composition also comprises one or more immune checkpoint inhibitors.

3. The pharmaceutical composition according to claim 2, It is characterized in that The immune checkpoint inhibitors include PD-1 monoclonal antibody, CTLA-4 monoclonal antibody or a combination thereof.

4. The pharmaceutical composition according to any one of claims 1 to 3, It is characterized in that The pharmaceutical composition is used in the treatment of colorectal cancer in mammals or humans to enhance immune cell infiltration and improve the sensitivity of immunotherapy.

5. A method for promoting the infiltration of immune cells in colorectal cancer of mammals or humans and improving the sensitivity of immunotherapy of colorectal cancer of mammals or humans using IGF1 R inhibitor I-OMe-Tyrphostin AG 538 or its related derivatives, It is characterized in that The method comprises administering an effective amount of AG-538 or its related derivatives to a mammal or a human in need thereof.

6. The method according to claim 5, It is characterized in that The administration methods include, but are not limited to, oral administration, injection or topical administration.

7. The method of claim 5, further comprising the step of administering one or more immune checkpoint inhibitors to the mammal or human.